We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed the most recent trading day at $27.92, moving +2.12% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.58%.
Prior to today's trading, shares of the biotechnology company had gained 11.73% outpaced the Medical sector's gain of 2.74% and the S&P 500's gain of 3.68%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company is predicted to post an EPS of -$1.95, indicating a 6600% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $925.77 million, indicating a 50.28% decline compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$9.59 per share and a revenue of $1.93 billion, representing changes of -8.12% and -40.37%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.15% increase. Moderna is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 90, positioning it in the top 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA - Free Report) closed the most recent trading day at $27.92, moving +2.12% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.58%.
Prior to today's trading, shares of the biotechnology company had gained 11.73% outpaced the Medical sector's gain of 2.74% and the S&P 500's gain of 3.68%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company is predicted to post an EPS of -$1.95, indicating a 6600% decline compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $925.77 million, indicating a 50.28% decline compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$9.59 per share and a revenue of $1.93 billion, representing changes of -8.12% and -40.37%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.15% increase. Moderna is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 90, positioning it in the top 37% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.